Wearable Device Outcomes in Patients with Duchenne Muscular Dystrophy Treated with Delandistrogene Moxeparvovec: Findings from EMBARK

Introduction Duchenne muscular dystrophy (DMD), an X-linked neuromuscular disease caused by pathogenic variants in the DMD gene coding for dystrophin production, leads to progressive muscle degeneration and loss of ambulation. Delandistrogene moxeparvovec is a recombinant adeno-associated virus vector-based gene transfer therapy designed to produce a functional micro-dystrophin protein, which protects the sarcolemmal membrane against contraction-induced injury and stabilizes or slow DMD disease progression. This study evaluated the efficacy and impact of delandistrogene moxeparvovec on DMD progression using wearable device-derived ambulatory endpoints measured in the community, including Stride Velocity 95th Centile (SV95C), over a 104-week period. Methods EMBARK, a Phase 3, multinational, randomized, double-blind, two-part, placebo-controlled study assessed the safety and efficacy of delandistrogene moxeparvovec in ambulatory patients with DMD aged ≥4 to <8 years. In Part 1 (52 weeks), 125 patients were randomized to receive delandistrogene moxeparvovec (n = 63) or placebo (n = 62). In Part 2 (52 weeks), patients crossed over to the other treatment arm. Wearable device-derived ambulation endpoints were pre-defined, including the pre-specified secondary endpoint of SV95C and other exploratory endpoints. Results Compliance with wearable use remained at >90% across most timepoints, with high average use time (>180 hours per interval). For patients treated with delandistrogene moxeparvovec in Part 1, at week 52, SV95C showed a nominally significant difference favoring delandistrogene moxeparvovec versus placebo (between-group least squares mean difference: 0.10 m/s 95% confidence interval [CI] 0.00, 0.19; p = 0.0402). Compared with placebo, improvements were seen in 95th percentile of stair-climbing velocity (0.06 m/s; 0.02, 0.11; p = 0.0081) and other exploratory endpoints, including stride length, stairs climbed, and distance walked. By week 104, 95th percentile of stride length, number of stairs climbed per unit time, and distance walked per unit time remained broadly stable, with only minimal changes from baseline. For patients treated in Part 2, these measures showed similar trends consistent with Part 1 results with improvements maintained over 52 weeks post-infusion. Conclusion Findings report the first digital stride-level data that show improvement or stabilization of DMD disease progression over 2 years in ambulatory patients treated with delandistrogene moxeparvovec in a clinical trial setting, consistent with traditional ambulatory functional outcomes. In line with pre-specified key secondary functional endpoints in EMBARK, including improvements in TTR and 10MWR, SV95C results support stabilization or slowing of DMD disease progression with delandistrogene moxeparvovec.

Authors

Publication Details

Journal
Digital Biomarkers
Published
2026-11-21
DOI
https://doi.org/10.1159/dib/acpag008
Primary Topic
Neurogenetic and Muscular Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Wearable Device Outcomes in Patients with Duchenne Muscular Dystrophy Treated with Delandistrogene Moxeparvovec: Findings from EMBARK

Alexander Peter Murphy, Louise R. Rodino‐Klapac, Stefanie Mason, Carol Reid et al.
Digital Biomarkers
Neurogenetic and Muscular Disorders Research
article

Wearable Device Outcomes in Patients with Duchenne Muscular Dystrophy Treated with Delandistrogene Moxeparvovec: Findings from EMBARK

Alexander Peter Murphy, Louise R. Rodino‐Klapac, Stefanie Mason, Carol Reid, Francesco Muntoni, Craig M. McDonald, Marianna Manfrini, Xiao Ni, Paul Strijbos
article en

Abstract

Introduction Duchenne muscular dystrophy (DMD), an X-linked neuromuscular disease caused by pathogenic variants in the DMD gene coding for dystrophin production, leads to progressive muscle degeneration and loss of ambulation. Delandistrogene moxeparvovec is a recombinant adeno-associated virus vector-based gene transfer therapy designed to produce a functional micro-dystrophin protein, which protects the sarcolemmal membrane against contraction-induced injury and stabilizes or slow DMD disease progression. This study evaluated the efficacy and impact of delandistrogene moxeparvovec on DMD progression using wearable device-derived ambulatory endpoints measured in the community, including Stride Velocity 95th Centile (SV95C), over a 104-week period. Methods EMBARK, a Phase 3, multinational, randomized, double-blind, two-part, placebo-controlled study assessed the safety and efficacy of delandistrogene moxeparvovec in ambulatory patients with DMD aged ≥4 to <8 years. In Part 1 (52 weeks), 125 patients were randomized to receive delandistrogene moxeparvovec (n = 63) or placebo (n = 62). In Part 2 (52 weeks), patients crossed over to the other treatment arm. Wearable device-derived ambulation endpoints were pre-defined, including the pre-specified secondary endpoint of SV95C and other exploratory endpoints. Results Compliance with wearable use remained at >90% across most timepoints, with high average use time (>180 hours per interval). For patients treated with delandistrogene moxeparvovec in Part 1, at week 52, SV95C showed a nominally significant difference favoring delandistrogene moxeparvovec versus placebo (between-group least squares mean difference: 0.10 m/s 95% confidence interval [CI] 0.00, 0.19; p = 0.0402). Compared with placebo, improvements were seen in 95th percentile of stair-climbing velocity (0.06 m/s; 0.02, 0.11; p = 0.0081) and other exploratory endpoints, including stride length, stairs climbed, and distance walked. By week 104, 95th percentile of stride length, number of stairs climbed per unit time, and distance walked per unit time remained broadly stable, with only minimal changes from baseline. For patients treated in Part 2, these measures showed similar trends consistent with Part 1 results with improvements maintained over 52 weeks post-infusion. Conclusion Findings report the first digital stride-level data that show improvement or stabilization of DMD disease progression over 2 years in ambulatory patients treated with delandistrogene moxeparvovec in a clinical trial setting, consistent with traditional ambulatory functional outcomes. In line with pre-specified key secondary functional endpoints in EMBARK, including improvements in TTR and 10MWR, SV95C results support stabilization or slowing of DMD disease progression with delandistrogene moxeparvovec.

Digital Biomarkers
Neurogenetic and Muscular Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon